JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix

Oncotarget

Volumn 6, Issue 42, 2015, Pages 44373-44387

  Yin, Aijun ^a   Zhang, Qing ^a   Kong, Xiangnan ^a   Jia, Lin ^a   Yang, Ziyan ^a   Meng, Lihua ^a   Li, Li ^b   Wang, Xiao ^b   Qiao, Yunbo ^a   Lu, Nan ^b   Yang, Qifeng ^a   Shen, Keng ^c   Kong, Beihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Cervical neoplasia; Complementary; JAM3; Methylation; Triage

Indexed keywords

ADULT; ARTICLE; CADM1 GENE; CCNA1 GENE; CLINICAL ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DAPK1 GENE; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; FEMALE; GENE LOCUS; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; JAM3 GENE; ONCOGENE; PREDICTIVE VALUE; PROTEIN METHYLATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; AREA UNDER THE CURVE; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; GENETICS; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; POLYMERASE CHAIN REACTION; PRECANCER; REPRODUCIBILITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; JAM3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AREA UNDER CURVE; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; BIOMARKERS, TUMOR; CELL ADHESION MOLECULES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84953432123     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6250     Document Type: Article

References (47)

1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013; 132:1133-1145.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, EserS, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Visit: http://globocan iarc fr. 2014.
3. Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, ZhangQM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, ZhangX, Belinson JL, Sellors JW, Smith JS, etal. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. Int J Cancer. 2012; 131:2929-2938.
4. Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi S. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine. 2008; 26:M53-59.
5. Saxena U, Sauvaget C, Sankaranarayanan R. Evidence-based screening, early diagnosis and treatment strategy of cervical cancer for national policy in low- resource countries: example of India. Asian Pac J Cancer Prev. 2012; 13:1699-1703.
6. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A, Birembaut P, Kulasingam S, Sasieni P, Iftner T. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119:1095-1101.
7. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL, Canadian Cervical Cancer Screening Trial Study G. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357:1579-1588.
8. Bulkmans NW, Berkhof J, Rozendaal L, van KemenadeFJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370:1764-1772.
9. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32:S16-24.
10. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009; 112:293-299.
11. Kim JH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol. 2010; 116:99-104.
12. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT. Credentialing of DNA methylation assays for human genes as diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive women. Gynecol Oncol. 2014; 132:709-714.
13. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, VerpootenG, Dehaspe L, de Bock GH, Hollema H, van Criekinge W, Schuuring E, van der Zee AG, Wisman GB. A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer. 2012; 130:1861-1869.
14. Szalmas A, Konya J. Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol. 2009; 19:144-152.
15. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ, Snijders PJ, Steenbergen RD. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol. 2009; 219:327-336.
16. Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst. 2004; 96:294-305.
17. Koeneman MM, Kruitwagen RF, Nijman HW, SlangenBF, Van Gorp T, Kruse AJ. Natural history of high-grade cervical intraepithelial neoplasia: a review of prognostic biomarkers. Expert Rev Mol Diagn. 2015; 15:527-546.
18. Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 2013; 2013:519-619.
19. Saavedra KP, Brebi PM, Roa JC. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012; 4:13.
20. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT, Daalmeijer NF, Wilting SM, Heideman DA, Verheijen RH, Zaal A, van Baal WM, Berkhof J, Snijders PJ, Steenbergen RD. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer. 2011; 129:2218-2225.
21. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta. 2013; 424:53-65.
22. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012; 13:484-492.
23. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer. 2014; 14:395-405.
24. Yang N, Eijsink JJ, Lendvai A, Volders HH, Klip H, Buikema HJ, van Hemel BM, Schuuring E, van der Zee AG, Wisman GB. Methylation markers for CCNA1 and C13ORF18 are strongly associated with high-grade cervical intraepithelial neoplasia and cervical cancer in cervical scrapings. Cancer Epidemiol Biomarkers Prev. 2009; 18:3000-3007.
25. Siegel EM, Riggs BM, Delmas AL, Koch A, HakamA, Brown KD. Quantitative DNA methylation analysis of candidate genes in cervical cancer. PLoS One. 2015; 10:e0122495.
26. Yang N, Nijhuis ER, Volders HH, Eijsink JJ, Lendvai A, Zhang B, Hollema H, Schuuring E, Wisman GB, van der Zee AG. Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol. 2010; 32:131-143.
27. Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB, van der Zee AG, Snijders PJ, Steenbergen RD. CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer. 2013; 133:1293-1299.
28. Mersakova S, Visnovsky J, Holubekova V, Nachajova M, Kudela E, Danko J, Lasabova Z. Detection of methylation of the promoter region of the MAL and CADM1 genes by pyrosequencing in cervical carcinoma. Neuro Endocrinol Lett. 2014; 35:619-623.
29. Sun LL, Cao DY, Yang JX, Li H, Zhou XR, Song ZQ, Cheng XM, Chen J, Shen K. Population-based case-control study on DAPK1, RAR-beta2 and MGMT methylation in liquid-based cytology. Arch Gynecol Obstet. 2012; 285:1433-1439.
30. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA, Massuger LF, Verhoef VM, Bulten J, Melchers WJ, van der Zee AG, Bekkers RL, Wisman GB. DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women. Br J Cancer. 2014; 111:1095-1101.
31. Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, van Hemel BM, Voll M, Coelingh Bennink HJ, Schuuring E, Wisman GB, van der Zee AG. Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol. 2011; 120:280-283.
32. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92:690-698.
33. Baileff A. Cervical screening: patients' negative attitudes and experiences. Nurs Stand. 2000; 14:35-37.
34. Rogstad KE. The psychological impact of abnormal cytology and colposcopy. BJOG. 2002; 109:364-368.
35. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol. 1998; 91:973-976.
36. Wright TC, Jr., Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. American Society for C and Cervical Pathology-sponsored Consensus C. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197:340-345.
37. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, Conference ACG. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013; 121:829-846.
38. Arbyn M, Sasieni P, Meijer CJ, Clavel C, KoliopoulosG, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine. 2006; 24 Suppl 3:S3/78-89.
39. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003; 127:946-949.
40. Kurman RJ, Cancer IAfRo and Organization WH. (2014). WHO classification of tumours of female reproductive organs: International Agency for Research on Cancer.
41. Martin-Padura I, Lostaglio S, Schneemann M, WilliamsL, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998; 142:117-127.
42. Palmeri D, van Zante A, Huang CC, Hemmerich S, Rosen SD. Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells. J Biol Chem. 2000; 275:19139-19145.
43. Mandicourt G, Iden S, Ebnet K, Aurrand-Lions M, Imhof BA. JAM-C regulates tight junctions and integrin-mediated cell adhesion and migration. J Biol Chem. 2007; 282:1830-1837.
44. Hajjari M, Behmanesh M, Sadeghizadeh M, Zeinoddini M. Junctional adhesion molecules 2 and 3 may potentially be involved in progression of gastric adenocarcinoma tumors. Med Oncol. 2013; 30:380.
45. Langer HF, Orlova VV, Xie C, Kaul S, SchneiderD, Lonsdorf AS, Fahrleitner M, Choi EY, Dutoit V, Pellegrini M, Grossklaus S, Nawroth PP, Baretton G, Santoso S, Hwang ST, Arnold B, et al. A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis. Cancer Res. 2011; 71:4096-4105.
46. Fuse C, Ishida Y, Hikita T, Asai T, Oku N. Junctional adhesion molecule-C promotes metastatic potential of HT1080 human fibrosarcoma. J Biol Chem. 2007; 282:8276-8283.
47. Solomon D, Nayar R. (2004). The Bethesda System for reporting cervical cytology: definitions, criteria, and explanatory notes: Springer Science & Business Media.